Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Symptom Burden and Quality of Life among Women with HER 2 + Metastatic Breast Cancer

Symptom Burden and Quality of Life among Women with HER 2 + Metastatic Breast Cancer To the Editor: Recent analyses of patients with metastatic breast cancer (MBC) by subtype indicate that with the use of HER2‐directed therapy, patients with HER2 + MBC experience improved survival and may have a superior prognosis by comparison with other subtypes . As these women live longer and undergoing longer periods of cancer treatment, preserving their quality of life (QoL) becomes increasingly important. While most QoL research has focused on early stage breast cancer, existing studies in the metastatic setting suggest a sizable proportion of patients suffer multiple physical symptoms as well as emotional distress . However, these studies have been limited to the impact of metastatic disease during the first year after diagnosis . No data exist on patients who have survived for several years after a metastatic diagnosis. Given the need for research in these areas, we administered a cross‐sectional, web‐based survey of QoL among women with HER2 + MBC. This survey included women who met the following study criteria: aged 18 years or older; diagnosis of HER2 + breast cancer; diagnosis at any time with Stage IV/metastatic cancer; received breast cancer treatment in the prior month; and members of one of six US‐based independent breast http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png The Breast Journal Wiley

Symptom Burden and Quality of Life among Women with HER 2 + Metastatic Breast Cancer

Loading next page...
 
/lp/wiley/symptom-burden-and-quality-of-life-among-women-with-her-2-metastatic-I6kjI2vIro

References (14)

Publisher
Wiley
Copyright
Copyright © 2015 Wiley Periodicals, Inc.
ISSN
1075-122X
eISSN
1524-4741
DOI
10.1111/tbj.12374
pmid
25655357
Publisher site
See Article on Publisher Site

Abstract

To the Editor: Recent analyses of patients with metastatic breast cancer (MBC) by subtype indicate that with the use of HER2‐directed therapy, patients with HER2 + MBC experience improved survival and may have a superior prognosis by comparison with other subtypes . As these women live longer and undergoing longer periods of cancer treatment, preserving their quality of life (QoL) becomes increasingly important. While most QoL research has focused on early stage breast cancer, existing studies in the metastatic setting suggest a sizable proportion of patients suffer multiple physical symptoms as well as emotional distress . However, these studies have been limited to the impact of metastatic disease during the first year after diagnosis . No data exist on patients who have survived for several years after a metastatic diagnosis. Given the need for research in these areas, we administered a cross‐sectional, web‐based survey of QoL among women with HER2 + MBC. This survey included women who met the following study criteria: aged 18 years or older; diagnosis of HER2 + breast cancer; diagnosis at any time with Stage IV/metastatic cancer; received breast cancer treatment in the prior month; and members of one of six US‐based independent breast

Journal

The Breast JournalWiley

Published: Mar 1, 2015

There are no references for this article.